Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation

Song Xuea Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China

Yongping Zhanga Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China

Fuhong Liua Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China

Wenqiu Huanga Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China

Ri Xub Beijing Bo Fu Rui Gene Diagnostics Co., Ltd, Beijing, China

Jingbo Wanga Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaCorrespondence[email protected]

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors would like to thank Medjaden Inc. for editing and proofreading the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.

Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation

Information for

Open access

Opportunities

Help and information

Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation

Acknowledgments

Disclosure statement

Data availability statement

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature